Lymphoma News

FDA Approves Pembrolizumab (KEYTRUDA®) for Classical Hodgkin Lymphoma

New York, NY (March 14, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of pembrolizumab (KEYTRUDA ®) to treat patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three…

Lymphoma Research Foundation Publishes White Paper Outlining Key Issues From Oral Therapy Workshop

Lymphoma Research Foundation publishes White Paper to outline key issues discussed during Oral Therapies workshop In September 2015, The Lymphoma Research Foundation (LRF) convened scientists, clinicians, advocates, pharmaceutical industry representatives, and federal lawmakers and regulators for a workshop on Oral…